Pfizer Drops 3% on Surprise CFO Resignation

Pfizer (PFE) disclosed in an SEC filing that Executive Vice President and CFO Dave Denton notified the company on June 16 of his resignation, effective August 15. The stock fell 3% in after-hours trading despite the company reaffirming its 2026 financial guidance.

Background

Dave Denton has served as Pfizer's CFO since 2022, playing a key role in restructuring the company after declining COVID-19 vaccine revenues. Prior to Pfizer, he was CFO of Centene Corporation.

Reasons for Change

Pfizer did not provide a specific reason for Denton's resignation but stated it would immediately begin searching for a successor. The filing did not indicate any disagreements with management or the board.

Impact on Company

The resignation comes at a critical time for Pfizer as it seeks to strengthen its drug pipeline following patent expirations on key products. The temporary absence of a CFO could affect investor confidence, especially amid ongoing cost-cutting efforts.

Market Reaction

Pfizer shares fell 3% on the news, reflecting investor concern over management instability. However, the stock partially recovered after the company reaffirmed its 2026 guidance.